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The alterations in DNA methylation patterns [1–3], 
in particular the pattern of the global genomic DNA hy-
pomethylation [4–6] and genomic regional CpG-pro-
moter DNA hypermethylation of the tumor suppressor 
genes [7–10] are the characteristic general features 
of carcinogenesis in various models [11] focusing on 
the importance of epigenetic events in oncogenic 
transformation and tumor progression [12–17].
Genome-wide DNA hypomethylation is a consistent 
finding in human tumors, but the importance of this 
change for human tumorigenesis remains an open 
question. The biological significance of DNA hypo-
methylation in carcinogenesis is far from being clearly 
elucidated in details. In particular, the mechanisms of 
genomic instability caused by hypomethylation remain 
unclear. This hypomethylation of the genome largely 
affects the intergenic and intronic regions of the DNA, 
particularly repeat sequences and transposable ele-
ments [18], and is believed to result in chromosomal 
instability and increased mutation events [19]. Previ-
ously, we have revealed the association between the 
aberrant pattern of genomic DNA hypomethylation 
in peripheral blood lymphocytes of the patients with 
various solid cancers and the increase in genomic DNA 
content (hyperploidy); the same effects have been 
evident upon 5-azacytidine treatment in the culture of 
normal lymphocytes [20]. The aim of the present study 
was to analyze the association between genomic DNA 
hypomethylation in peripheral blood lymphocytes of 
cancer patients and normal lymphocytes treated with 
5-azacytidine and the alterations in chromatin orga-
nization in these cells. We suggest that the induced 
global DNA hypomethylation triggers dis-epigenetic 
morphological reprogramming of constitutive pericen-
tromeric heterochromatin on the extrachromosomal 
organization pathway. This may be one of the mecha-
nisms involving DNA hypomethylation in initiation and 
progression of cancer.
MATERIALS AND METHODS
The peripheral blood lymphocytes were obtained 
from blood samples taken from the patients with solid 
tumors: (thyroid gland cancer, n = 35; colorectal can-
cer, n = 26; breast cancer, n = 5; neuroblastoma, n = 8; 
Wilms tumor, n = 6). Lymphocytes from healthy donors 
were used as a control (n = 20). The permission from 
Bioethyc committee concerning the investigations 
conduction has been obtained.
The satellite DIG-pUC(Alu)- DNA repeats dot-
hybridization with cancer-associated genomic DNA 
hypomethylation and 5-azacytydine exposed genomic 
DNA  was performed. The mitogen-stimulated periph-
eral blood lymphocytes were cultured in RPM1640 
medium supplemented with 10% fetal serum. 5-Azacy-
tidine used as DNA demethylation reagent was added 
at the correct concentration of 10–5 M for 72 h. 
Cytomorphological study of metaphase chromo-
somes (n = 500, P < 0.001) and interphase nuclear 
lymphocytes (n = 500, P < 0.001) was conducted 
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using light and fluorescent microscopy with Giemsa, 
DAPI, and Hoechst 33258 staining, using microscope 
“Axiotar FL” (ZEISS, Germany) and “Scion Image” 
program (ZEISS, Germany). 
The statistic Program “Origin 6.1” was used to 
analyze the data obtained [20].
RESULTS AND DISCUSSION
As shown in Fig. 1, DNA content in the peripheral 
blood lymphocytes of the patients with various histo-
logical forms (n = 5, thyroid cancer, colorectal cancer, 
breast cancer, neuroblastoma and Wilms tumor) of 
cancer increases similarly to that in the lymphocytes 
of the healthy donors (n = 5) cultured in the presence 
of 5-azacytidine (10–5 M) as DNA demethylation re-
agent (Table 1). Simultaneously, the targeted major 
pericentromeric (Alu)-DNA repeats amplification in 
genomic lymphocyte DNA of cancer patients as well as 
in 5-azacytidine exposed cultured healthy lymphocyte 
DNA have been revealed (Fig. 2, a, b). This suggests 
that pericentromeric/centromeric Alu-repeats ampli-
fication feature is the sensitive molecular sensor as-
sociating with targeted genomic DNA demethylation 
and evidently contributs to nuclei pericentromeric het-
erochromatinization both in cancer patients and upon 
experimental 5-azacytidine exposed lymphocytes. 
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Fig. 1. The increase in nuclear DNA content of interphase pe-
ripheral blood lymphocytes from the patients with solid cancer 
(red), healthy (gray) and healthy lymphocytes after 5-azacytidine 
treatment (stroke) using DAPI and Hoechst 33258 staining
*No difference.
Table 1. The increasing heterochromatin fluorescense of the interphasic  
lymphocytes from solid cancer patients (A) and upon 5-azacytidine 
treatment (B) using DAPI and Hoechst staining DAPI
Variant M ± m > % (C) P
Control (C) 134 ± 11.86; n = 5 P1 < 0.001
Cancer (А) 252 ± 32.08; n = 5 88.06 ± 7.04 P2 < 0.001
5-АzaCyt (B) 216 ± 19.32; n = 5 61,19 ± 4,88 P3 > 0.05
(t = 0.961)
Hoechst 33258
M ± m > % (C) P
Control (C) 307 ± 21.34; n = 5 P1 < 0.005
Cancer (А) 558 ± 47.13; n = 5 81.75 ± 5.32 P2 < 0.005
5-АzaCyt (B) 526 ± 36.95; n = 5 71. 3 ± 6.85 P3 > 0.05
(t = 0.021)
Notes: 500 lymphocytes from every person were analysed. P1 — P value 
between (C) and (A); P2 — P value between (C) and (B); P3 — no difference 
between (A) and (B).
The analysis of heterochromatin features in the meta-
phase chromosomes of the blood lymphocytes taken from 
the patients with solid cancer (Table 2) demonstrated the 
crucial decondensation of constitutive pericentromeric/
centromeric heterochromatin (Fig. 3, a). At the same time, 
we have found the exact association of the decondensed 
pericentromeric heterochromatin regions with their mor-
phological abnormality, in particular the latent polytene 
chromomerization events in the metaphase chromosomes 
of the peripheral blood lymphocytes of cancer patients.
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Fig. 2. Dot-DIG (Alu)-repeats amplification in cancer patients (a) and 
in cultured healthy lymphocytes in the presence of different concentra-
tions of 5-azacytidine (b). DIG-pUC(ALU) was used as a probe. a, 1 — 
DNA from healthy lymphocytes; 2 — the embryonic DNA; 3 — DNA 
from the solid cancer patient lymphocytes; A — neuroblastoma; B — 
breast cancer; C — Ewing sarcoma; E — colorectal cancer; F — thyroid 
gland cancer. b, I — 50 ng lymphocyte DNA; II — 25 ng lymphocyte DNA
Table 2. The crucial patterns of mitotic pericentromeric heterochromatin 
in cancer patients lymphocytes
Type of tumors
Metaphase de-
condensation 
heteropycnisis
Metaphase 
latent chro-
momerization
Inter-
phase 
nuclei
Thyroid gland cancer (n = 35) ++++ +++ +++
Colorectal cancer (n = 26) ++++ +++ +++
Breast cancer (n = 5) ++++ +++ +++
Children`s neuroblastoma (n = 8) ++++ +++ ++
Children՚s Wilms tumor (n = 6) ++++ ++ ++
Control (n = 20) – – –
Notes: 500 metaphases and 500 interphasic nuclei were investigated from 
each patient. [+; +++++] — the relative cytomorphological heterochromatin 
phenotype index.
Fig. 3, b, 1 demonstrates typical chromomerization 
of pericentromeric/centromeric heterochromatin at the 
metaphase stage of the patient with the advanced thyroid 
cancer. The cancer-associated latent polyteny of pericen-
tromeric/centromeric heterochromatin regions also ap-
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peared in its distinctive tendency to bilateral ectopic con-
tacts between metaphase sister chromatids (Fig. 3, b, 2). 
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Fig. 3. a, Decondensation of pericentromeric/centromeric hetero-
chromatin in metaphase chromosomes of the blood lymphocytes 
taken from the patients with solid cancers. b, 1 — the latent polytene 
chromomerization of pericentromeric heterochromatin of metaphase 
chromosomes taken from the blood lymphocytes of patient with the 
thyroid cancer stage IV. 2 — the bilateral ectopic conjugation of chro-
momeric heterochromatin regions between the sister chromatids. 
C, 1 — cancer-associated nuclear heteropycnosis of constitutive in-
terphasic heterochromatin by DAPI staining. 2 — interphasic nuclear 
polytene chromomerization of constitutive heterochromatin with 
α-dense and β-looping heterochromatin formation by Giemsa staining
Cytomorphological analyses of DAPI and Giemsa 
stained cells has shown that the development of 
heteropycnosis in interphasic nuclei of lymphocytes 
is evident both in cancer patients (Fig. 3, c,1, 2) and 
upon exposure of the normal mitogen-stimulated 
lymphocytes to 5-azacytidine  as demethylating agent 
(Fig. 4). In the case of the lymphocytes of cancer 
patients, the interphasic nuclear heterochromatini-
zation comprises the formation of massive hetero-
chromatinic granules, chromocenters, composed 
of dense α-heterochromatin and friable reticular 
β-heterochromatin (Fig. 3, c, 2) as distinctive ele-
ments of the latent polyteny features. At the same time, 
5-azacytidine directly induced the irreversible nuclear 
heteropycnosis by forming massive chromocenters in 
normal interphasic lymphocytes, cultured in the pres-
ence of 10-5 М 5-azacytidine for 72 h (see Fig. 4). 
Control (Giemsa)
(interphasic lymphocyte 
of healthy donor)
Control + 5-azacytidine (Giemsa)
(lymphocyte of healthy donor upon 
5-azacytidine demethylation treatment)
Fig. 4. The formation of the massive chromocenters of inter-
phasic constitutive heterochromatin induced by 5-azacytidine 
DNA demethylating agent in the normal lymphocytes cultured 
for 72 h (Giemsa staining)
We believe that the morphological alterations of 
pericentromeric/centromeric heterochromatin may 
be the evidence of the causal connection of aberrant 
genomic DNA hypomethylation/demethylation with 
the genomic latent polyteny events, as it was shown 
on targeted metaphase chromomerization and inter-
phasic nuclear heteropycnosis using the overreplica-
tion mechanism of the constitutive pericentromeric 
heterochromatin.
We have earlier revealed that genomic hypomethy-
lation in different solid cancers at the level of peripheral 
blood lymphocytes reflects the global pericentromeric 
(Alu) DNA satellites demethylation [20]. As shown in 
the present study, the hypomethylation may run in 
parallel to the critical decondensation of constitutive 
pericentromeric/centromeric heterochromatin of 
metaphase chromosomes representing the significant 
cytoepigenetic deregulation in tumor progression [21]. 
The association between the metaphase chromosome 
decondensation and distinctive chromomere organi-
zation of heterochromatin regions of lymphocytes on 
the one hand and hypomethylation state induced by 
5-azacytidine as demethylating agent has been de-
monstrated also by other authors [22]. It could be sug-
gested that genomic hypomethylation is associated 
with the induction of dis-epigenetic morphological 
constitutional pericentromeric/centromeric hetero-
chromatin alteration as the latent polyteny events. We 
have observed that the characteristic morphological 
features of the nuclei of normal lymphocytes treated 
with 5-azacytidine are similar to that observed in the 
lymphocytes of cancer patients. It is interesting that 
in several studies 5-azacytidine treatment of tumor 
cell lines has been shown to increase their metastatic 
potential [23, 24].
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Therefore, we have observed three discrete latent 
polyteny features of mitotic constitutive heterochroma-
tin in lymphocytes of cancer patients: a) the targeted 
metaphase heterochromatin chromomerization; b) the 
ectopic conjugation events between sister chromatids 
in chromomerized heterochromatin regions; and c) the 
targeted nuclear heteropycnosis during interphasic 
heterochromatinization along with massive chromo-
centers formation.
We suppose that genomic DNA methylation implies 
the strategic protection from the latent polyteny “inva-
sion” of mitotic genome with the development of the 
global genomic, chromosomal and genetic imbalances. 
Therefore, the aberrant epigenetic DNA hypomethyla-
tion may be one of the neoplastic factosr initiating the 
latent polyteny “invasion” of mitotic genome during the 
somatic cellular malignant transformation.
The formation of the friable reticular β-hetero-
chro matin may result in the disordered gene expres-
sion and DNA replication (Fig. 5). As is well known, 
β-heterochromatin loops can be characterized by 
very active gene expression and by DNA amplification, 
mainly, by satellite and mobile genetic DNA sequences 
[25], contributing to the global mitotic disturbances 
leading to the somatic cellular malignant transforma-
tion. Chen T. et al. recently stated that global DNA 
hypomethylation in carcinogenesis leads to “mitotic 
catastrophe” but the details of this process have not 
yet been explained [26]. The induction of DNA hypo-
methylation may represent the molecular basis of the 
progressive latent polyteny events of pericentromeric/
centromeric heterochromatin, which may be regarded 
as one of the factors contributing cancer progression. 
The findings might be important regarding the potential 
use of the substances preventing DNA hypomethyla-
tion for the therapy of the malignancies [27, 28].
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Fig. 5. The schematic organization of pericentromeric heterochro-
matin in mitotic (a) and polytene chromosomes (b); black regions — 
α-heterochromatin, white regions — β-heterochromatin [25]
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ИЗМЕНЕНИЯ КОНСТИТУТИВНОГО ПЕРИЦЕНТРОМЕРНОГО 
ГЕТЕРОХРОМАТИНА В ЛИМФОЦИТАХ ОНКОБОЛЬНЫХ 
И ЛИМФОЦИТАХ, ОБРАБОТАННЫХ 5-АЗАЦИТИДИНОМ, 
АССОЦИИРОВАННЫЕ С ДНК ГИПОМЕТИЛИРОВАНИЕМ
ДНК-гипометилирование играет ключевую роль в канцерогенезе. Маллигнизация, как и прогрессия опухоли, сопровождается 
увеличением гипометилирования ДНК в опухолевых клетках. Тем не менее до сих пор вопросы эволюции дис-эпигенетических 
геномных изменений в соматической клеточной злокачественной трансформации, связанной с ДНК-гипометилированием, 
остаются невыясненными. Цель: исследовать взаимоотношения между характером геномного ДНК-гипометилирования и 
ДНК-гиперплоидностью. Методы: в модельной системе ДНК-деметилирования 5-азацитидином обрабатывали митоген-
стимулированные лимфоциты и лимфоциты периферической крови онкобольных с солидными опухолями. Содержание ДНК 
определялось на основе количественной DAPI и Hoechst 33258 флуоресценции интерфазных лимфоцитов. Фитогемагглютинин-
стимулированная культура лимфоцитов использовалась для исследования метафазных хромосом и интерфазных ядер с 
помощью световой и флуоресцентной микроскопии. Результаты: модельное действие 5-азацитидина увеличивает сомати-
ческую ДНК-гиперплоидность, которая сопровождается направленной амплификацией основных перицентромерных Alu 
ДНК-повторов, подобно таковой при онкологическом процессе, ассоциированном с геномным гипометилированием, что 
вносит вклад в развитие ядерного гетеропикноза. Выводы: выявлено, что индуцированное глобальное гипометилирование 
ДНК запускает дис-эпигенетическое репрограммирование конститутивного перицентромерного гетерохроматина по пути 
экстрахромосомной организации, как показано в развитии латентной политении гетерохроматина, которая является одним 
из ключевых механизмов вовлечения гипометилирования в инициацию развития и прогрессию опухолей.
Ключевые слова: ДНК-гипометилирование, 5-азацитидин, латентная политения, конститутивный перицентромерный 
гетерохроматин.
Copyright © Experimental Oncology, 2008
